BCL2 and neoplasm: Co-IP of the other recurrent tumor confirmed our in vivo “retreatment” findings that the tumors did not change their Bcl-2 family dependence pattern in response to treatment with ABT-199, as the majority of Bim remained bound to Bcl-2 (Fig. 5b).